These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1294 related articles for article (PubMed ID: 14656927)

  • 1. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
    Passier R; Zeng H; Frey N; Naya FJ; Nicol RL; McKinsey TA; Overbeek P; Richardson JA; Grant SR; Olson EN
    J Clin Invest; 2000 May; 105(10):1395-406. PubMed ID: 10811847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
    Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
    Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
    Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
    Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
    Musarò A; McCullagh KJ; Naya FJ; Olson EN; Rosenthal N
    Nature; 1999 Aug; 400(6744):581-5. PubMed ID: 10448862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
    Wilkins BJ; Molkentin JD
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1178-91. PubMed ID: 15336966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
    Braz JC; Bueno OF; Liang Q; Wilkins BJ; Dai YS; Parsons S; Braunwart J; Glascock BJ; Klevitsky R; Kimball TF; Hewett TE; Molkentin JD
    J Clin Invest; 2003 May; 111(10):1475-86. PubMed ID: 12750397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
    Diedrichs H; Chi M; Boelck B; Mehlhorn U; Schwinger RH
    Eur J Heart Fail; 2004 Jan; 6(1):3-9. PubMed ID: 15012912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
    Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
    J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
    Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
    Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
    Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
    PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
    Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
    Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
    Molkentin JD
    Cardiovasc Res; 2004 Aug; 63(3):467-75. PubMed ID: 15276472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
    Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
    Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
    Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
    J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction.
    Bueno OF; Lips DJ; Kaiser RA; Wilkins BJ; Dai YS; Glascock BJ; Klevitsky R; Hewett TE; Kimball TR; Aronow BJ; Doevendans PA; Molkentin JD
    Circ Res; 2004 Jan; 94(1):91-9. PubMed ID: 14615291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.
    Liang Q; Bueno OF; Wilkins BJ; Kuan CY; Xia Y; Molkentin JD
    EMBO J; 2003 Oct; 22(19):5079-89. PubMed ID: 14517246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.